Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

Blood
Charles C ChuNicholas Chiorazzi

Abstract

Many B-cell chronic lymphocytic leukemia (CLL) monoclonal antibodies (mAbs) can be grouped into subsets based on nearly identical stereotyped sequences. Subset 6 CLL mAbs recognize nonmuscle myosin heavy chain IIA (MYHIIA). Herein, we report that during apoptosis, MYHIIA becomes exposed on the cell surface of a subgroup of apoptotic cells, allowing subset 6 CLL mAbs to bind with it. Because other non-subset 6 CLL mAbs interact with apoptotic cells, 26 CLL mAbs, including 24 not belonging to subset 6, were tested for reactivity with MYHIIA-exposed apoptotic cells (MEACs). More than 60% of CLL mAbs bound MEACs well; most of these mAbs expressed unmutated IGHV (15 of 16) and belonged to a stereotyped subset (14 of 16). Binding to MEACs inversely correlated with the degree of IGHV mutation. Interestingly, high binding to MEACs significantly correlated with poor patient survival, suggesting that the basis of IGHV mutation status as a CLL prognostic factor reflects antigen binding. Finally, natural antibodies from human serum also reacted with MEACs. Taken together, our data indicate that a large proportion of CLL clones emerge from natural antibody-producing cells expressing immunoglobulins that recognize MEACs, and that this reacti...Continue Reading

References

Jan 1, 1989·The Journal of Experimental Medicine·Z M SthoegerN Chiorazzi
Oct 1, 1988·Journal of Autoimmunity·B M BrökerP Collins
Sep 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kathleen N PotterBrian J Sutton
Mar 5, 2003·Annual Review of Immunology·Nicholas Chiorazzi, Manlio Ferrarini
Apr 23, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Qi LiElise F Stanley
Aug 18, 2004·The Journal of Experimental Medicine·Bradley T MessmerNicholas Chiorazzi
Dec 21, 2004·Springer Seminars in Immunopathology·Christoph J Binder, Gregg J Silverman
Feb 16, 2005·The Journal of Clinical Investigation·Bradley T MessmerNicholas Chiorazzi
Feb 25, 2005·The New England Journal of Medicine·Nicholas ChiorazziManlio Ferrarini
Mar 8, 2005·Journal of Biochemistry·Masahiko KatoShinobu Imajoh-Ohmi
Apr 15, 2005·Molecular Immunology·YuFeng PengKeith B Elkon
Jan 5, 2006·The Journal of Experimental Medicine·Ming ZhangMichael C Carroll
Sep 27, 2006·Cancer Science·André S BachmannCarl-Wilhelm Vogel
Mar 3, 2007·The Journal of Clinical Investigation·Yifat MerblIrun R Cohen
Dec 22, 2007·Journal of Cell Science·Mary Anne Conti, Robert S Adelstein
Aug 20, 2008·British Journal of Haematology·Julien DefoicheLuc Willems
Nov 4, 2008·Nucleic Acids Research·Marie-Paule LefrancPatrice Duroux
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

Aug 13, 2013·Seminars in Cancer Biology·Lesley-Ann SuttonKostas Stamatopoulos
Nov 14, 2012·Cell Research·Nicholas Chiorazzi, Dimitar G Efremov
Sep 22, 2011·Nature Immunology·Lixin RuiLouis M Staudt
Mar 2, 2013·Nature Reviews. Drug Discovery·Ryan M Young, Louis M Staudt
Oct 24, 2012·The Journal of Experimental Medicine·Marc SeifertRalf Küppers
Oct 2, 2012·The Journal of Clinical Investigation·Gianluca GaidanoRiccardo Dalla-Favera
Jan 18, 2011·Hematology·Mark C Lanasa
Jan 19, 2011·Haematologica·Kate HodgsonCarol Moreno
Sep 14, 2012·Mediterranean Journal of Hematology and Infectious Diseases·Efterpi KostareliKostas Stamatopoulos
Nov 22, 2012·Mediterranean Journal of Hematology and Infectious Diseases·Dimitar G EfremovLuca Laurenti
Aug 31, 2013·Annual Review of Pathology·Suping Zhang, Thomas J Kipps
Jan 9, 2014·Leukemia & Lymphoma·Andreas AgathangelidisKostas Stamatopoulos
Jul 3, 2015·Leukemia & Lymphoma·Richard Rosenquist
Mar 23, 2011·Expert Review of Anticancer Therapy·Marco FangazioGianluca Gaidano
Mar 29, 2011·Expert Opinion on Investigational Drugs·Dimitar G Efremov, Luca Laurenti
Oct 21, 2015·Proceedings of the National Academy of Sciences of the United States of America·Ryan M YoungLouis M Staudt
Apr 9, 2013·Hematology/oncology Clinics of North America·Yair HerishanuAdrian Wiestner
Apr 9, 2013·Hematology/oncology Clinics of North America·Nikos Darzentas, Kostas Stamatopoulos
Sep 5, 2015·European Journal of Immunology·Richard R Hardy, Kyoko Hayakawa
Jul 7, 2015·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Trisha A RettigSherry D Fleming
Sep 30, 2010·Journal of Immunological Methods·Edgar D CharlesLynn B Dustin
Sep 25, 2010·Seminars in Cancer Biology·Anders RosénRichard Rosenquist
Apr 25, 2015·Annals of the New York Academy of Sciences·Kyoko HayakawaRichard R Hardy
May 2, 2015·Annals of the New York Academy of Sciences·Yue-Sheng LiRichard R Hardy
Sep 3, 2013·British Journal of Haematology·Kirsty Cuthill, Stephen Devereux

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.